These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26135382)

  • 1. Is carvedilol better than other beta-blockers for heart failure?
    Rain C; Rada G
    Medwave; 2015 Jun; 15 Suppl 1():e6168. PubMed ID: 26135382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
    Wikstrand J; Wedel H; Castagno D; McMurray JJ
    J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
    Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-blockers for heart failure: why you should use them more.
    Ong HT; Kow FP
    J Fam Pract; 2011 Aug; 60(8):472-7. PubMed ID: 21814642
    [No Abstract]   [Full Text] [Related]  

  • 5. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
    Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):81-90. PubMed ID: 27859924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).
    DiNicolantonio JJ; Lavie CJ; Fares H; Menezes AR; O'Keefe JH
    Am J Cardiol; 2013 Mar; 111(5):765-9. PubMed ID: 23290925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
    Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
    Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.
    Kveiborg B; Major-Petersen A; Christiansen B; Torp-Pedersen C
    Vasc Health Risk Manag; 2007; 3(1):31-7. PubMed ID: 17583173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carvedilol versus other beta-blockers in heart failure.
    Doggrell SA
    Expert Opin Investig Drugs; 2001 May; 10(5):971-80. PubMed ID: 11322870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
    Fowler MB
    Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
    Poole-Wilson PA
    Am J Cardiol; 2004 May; 93(9A):40B-2B. PubMed ID: 15144936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
    Bauman JL; Talbert RL
    J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
    Díez Manglano J
    Rev Clin Esp; 2005 Apr; 205(4):149-56. PubMed ID: 15860185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.
    Lin TY; Chen CY; Huang YB
    Int J Cardiol; 2017 Mar; 230():378-383. PubMed ID: 28041715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.
    Wai B; Kearney LG; Hare DL; Ord M; Burrell LM; Srivastava PM
    Cardiovasc Diabetol; 2012 Feb; 11():14. PubMed ID: 22330091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.
    Lee S; Spencer A
    J Fam Pract; 2001 Jun; 50(6):499-504. PubMed ID: 11401736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure.
    Packer M
    Am J Cardiol; 1997 Dec; 80(11A):46L-54L. PubMed ID: 9412542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do pharmacological differences among beta-blockers affect their clinical efficacy in heart failure?
    Di Lenarda A; Sabbadini G; Sinagra G
    Cardiovasc Drugs Ther; 2004 Mar; 18(2):91-3. PubMed ID: 15293370
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of beta-blockers on mortality in chronic heart failure.
    Hart SM
    Ann Pharmacother; 2000 Dec; 34(12):1440-51. PubMed ID: 11144703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.